(Updates shares in the fifth paragraph.)
Feb. 3 (Bloomberg) -- Cosmo Pharmaceuticals SpA, the Italian developer of a dye to detect pre-cancerous lesions, has shelved its search for a partner and will market the product itself in the U.S. using the money it gained from the $2.6 billion sale of Santarus Inc.
Cosmo plans to remain independent, Mauro Ajani, the company’s founder and chief executive officer, said in a Jan. 31 interview, 15 months after saying he was considering the company’s “way out.” Instead, Cosmo plans to hire as many as 150 people to sell its Methylene Blue MMX in the U.S. if the dye is approved next year, and seek a secondary Nasdaq listing.
The company, which had a partnership with Santarus for the experimental antibiotic rifamycin that included a stake in the San Diego-based company, made $200 million when Raleigh, North Carolina-based Salix Pharmaceuticals Ltd bought Santarus in January. Salix had to return rifamycin to Cosmo because it has a similar antibiotic.
“With $200 million you can change your idea,” Ajani said at the company’s headquarters in Lainate, outside Milan. “With rifamycin back, and with the money, we started to think, can we do in-house the marketing and the commercialization of this product? The answer at the end of the day is yes, we can.”
Cosmo fell 2.1 percent to 91.75 Swiss francs at 2:25 p.m. in Zurich, giving the company a market value of 1.4 billion Swiss francs ($1.5 billion). The shares, which trade in Switzerland, almost doubled in the past year through Jan. 31, making them one of the top 10 performers in the Swiss Performance Index of 208 companies.
Cosmo expects results by the end of this year from a late- stage trial of Methylene Blue MMX, which identifies pre- cancerous lesions in the colon. The dye, administered in a tablet taken before a colonoscopy, is designed to improve on the white light currently used in the procedure, which doesn’t detect some lesions, and a sprayed dye that is rarely used because of the mess it involves.
Methylene Blue MMX may reach sales of $300 million, according to Peter Welford, an analyst at Jefferies LLC in London.
Cosmo, which gets royalties on medicines sold by Shire Plc and Santarus, expects total revenue to almost triple to 158 million euros ($213 million) next year from an estimated 56 million euros last year, it said in a Jan. 31 presentation to investors.
Ajani, who founded Cosmo in 1997, took it public 10 years later and is its majority shareholder, said last week he plans to step aside as CEO to focus on strategic decision-making, while handing the helm to Alessandro Della Cha.
--With assistance from Naomi Kresge in Berlin. Editors: Kim McLaughlin, Srinivasan Sivabalan